{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Precigen%2C+Inc", "query": { "sponsor": "Precigen, Inc" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T09:04:58.599Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05694364", "title": "Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Acute Lymphoblastic Leukemia", "Diffuse Large B Cell Lymphoma", "Triple Negative Breast Cancer Malignancies" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "PRGN-3007", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-01-25", "completion_date": "2024-04-18", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-28T09:04:58.599Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05694364" }, { "nct_id": "NCT04724980", "title": "Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Respiratory Papillomatosis", "Papillomavirus Infections", "Papillomaviridae" ], "interventions": [ { "name": "PRGN-2012 - Phase I; Dose Level 1", "type": "DRUG" }, { "name": "PRGN-2012 - Phase I; Dose Level 2", "type": "DRUG" }, { "name": "PRGN-2012 - Phase II; Dose Level 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Precigen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-03-16", "completion_date": "2026-06-05", "has_results": false, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-09-28T09:04:58.599Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04724980" }, { "nct_id": "NCT03907527", "title": "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Refractory Fallopian Tube Carcinoma", "Refractory Ovarian Carcinoma", "Refractory Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC V8", "Stage III Ovarian Cancer AJCC V8", "Stage III Primary Peritoneal Cancer AJCC V8", "Stage IIIA Fallopian Tube Cancer AJCC V8", "Stage IIIA Ovarian Cancer AJCC V8", "Stage IIIA Primary Peritoneal Cancer AJCC V8", "Stage IIIA1 Fallopian Tube Cancer AJCC V8", "Stage IIIA1 Ovarian Cancer AJCC V8", "Stage IIIA2 Fallopian Tube Cancer AJCC V8", "Stage IIIA2 Ovarian Cancer AJCC V8", "Stage IIIB Fallopian Tube Cancer AJCC V8", "Stage IIIB Ovarian Cancer AJCC V8", "Stage IIIB Primary Peritoneal Cancer AJCC V8", "Stage IIIC Fallopian Tube Cancer AJCC V8", "Stage IIIC Ovarian Cancer AJCC V8", "Stage IIIC Primary Peritoneal Cancer AJCC V8", "Stage IV Fallopian Tube Cancer AJCC V8", "Stage IV Ovarian Cancer AJCC V8", "Stage IV Primary Peritoneal Cancer AJCC V8", "Stage IVA Fallopian Tube Cancer AJCC V8", "Stage IVA Ovarian Cancer AJCC V8", "Stage IVA Primary Peritoneal Cancer AJCC V8", "Stage IVB Fallopian Tube Cancer AJCC V8", "Stage IVB Ovarian Cancer AJCC V8", "Stage IVB Primary Peritoneal Cancer AJCC V8" ], "interventions": [ { "name": "PRGN-3005 UltraCAR-T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Precigen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 71, "start_date": "2019-04-30", "completion_date": "2028-11-15", "has_results": false, "last_update_posted_date": "2024-11-08", "last_synced_at": "2026-09-28T09:04:58.599Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Seattle, Washington", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907527" }, { "nct_id": "NCT06538480", "title": "Zopa Retreatment and Vector Shedding in Adults With RRP", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Recurrent Respiratory Papillomatosis", "Papillomavirus Infection", "Papillomaviridae" ], "interventions": [ { "name": "Zopapogene imadenovec (Zopa)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Precigen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-07-11", "completion_date": "2028-12-02", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-09-28T09:04:58.599Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Bethesda, Maryland • Cincinnati, Ohio", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06538480" }, { "nct_id": "NCT03927261", "title": "PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "PRGN-3006 T Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Precigen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2019-05-20", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2024-11-08", "last_synced_at": "2026-09-28T09:04:58.599Z", "location_count": 2, "location_summary": "Tampa, Florida • Rochester, Minnesota", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03927261" }, { "nct_id": "NCT06157151", "title": "PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "HPV-Related Carcinoma", "HPV-Related Malignancy", "Recurrent Cervical Carcinoma", "Metastatic Cervical Cancer" ], "interventions": [ { "name": "PRGN-2009 plus Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Precigen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-11-11", "completion_date": "2030-11-30", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-28T09:04:58.599Z", "location_count": 3, "location_summary": "Little Rock, Arkansas • Bethesda, Maryland • Seattle, Washington", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06157151" }, { "nct_id": "NCT03409627", "title": "Novel INXN-4001 Triple Effector Plasmid in Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Heart Failure", "Cardiovascular Diseases", "Heart-Assist Device" ], "interventions": [ { "name": "INXN-4001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Triple-Gene, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-04-09", "completion_date": "2020-08-12", "has_results": false, "last_update_posted_date": "2020-12-04", "last_synced_at": "2026-09-28T09:04:58.599Z", "location_count": 2, "location_summary": "Tucson, Arizona • Cincinnati, Ohio", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03409627" } ] }